CO6470880A2 - Soluciones para infusión e inyección de diacetato de ipamorelina. - Google Patents

Soluciones para infusión e inyección de diacetato de ipamorelina.

Info

Publication number
CO6470880A2
CO6470880A2 CO11170483A CO11170483A CO6470880A2 CO 6470880 A2 CO6470880 A2 CO 6470880A2 CO 11170483 A CO11170483 A CO 11170483A CO 11170483 A CO11170483 A CO 11170483A CO 6470880 A2 CO6470880 A2 CO 6470880A2
Authority
CO
Colombia
Prior art keywords
ipamorelin
injection
diacetate
infusion
solutions
Prior art date
Application number
CO11170483A
Other languages
English (en)
Inventor
Garcia Silvina Rubio
Daniel Beidler
Helle Weibel
Riccardo Braglia
Original Assignee
Helssin Therapeutics U S Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6470880(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helssin Therapeutics U S Inc filed Critical Helssin Therapeutics U S Inc
Publication of CO6470880A2 publication Critical patent/CO6470880A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Soluciones de inyección e infusión de ipamorelina, que tienen la siguiente composición: a) ipamorelina solubilizada mediante aproximadamente dos equivalentes molares de ácido acético (diacetato de ipamorelina), en una cantidad de 0.001 a 20%, con base en el peso de la base libre de ipamorelina; b) un exceso molar de ácido, preferiblemente ácido acético, en una cantidad suficiente para dar un pH de por lo menos 3 y menos de 7; c) opcionalmente de 0.1 a 30% de uno o más auxiliares de formulación; y d) cantidad suficiente de agua hasta alcanzar 100%; todos los porcentajes se basan sobre el peso total de la solución.
CO11170483A 2009-06-12 2011-12-12 Soluciones para infusión e inyección de diacetato de ipamorelina. CO6470880A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18659509P 2009-06-12 2009-06-12

Publications (1)

Publication Number Publication Date
CO6470880A2 true CO6470880A2 (es) 2012-06-29

Family

ID=42272260

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11170483A CO6470880A2 (es) 2009-06-12 2011-12-12 Soluciones para infusión e inyección de diacetato de ipamorelina.

Country Status (24)

Country Link
US (1) US20100317581A1 (es)
EP (1) EP2440180B1 (es)
JP (1) JP2012529510A (es)
KR (1) KR20120030530A (es)
CN (1) CN102481251A (es)
AU (1) AU2010259102B2 (es)
BR (1) BRPI1012931A2 (es)
CA (1) CA2765233A1 (es)
CL (1) CL2011003131A1 (es)
CO (1) CO6470880A2 (es)
CR (1) CR20110618A (es)
CU (1) CU20110232A7 (es)
DO (1) DOP2011000383A (es)
EA (1) EA201270011A1 (es)
EC (1) ECSP11011516A (es)
GT (1) GT201100318A (es)
MX (1) MX2011013113A (es)
NI (1) NI201100212A (es)
NZ (1) NZ596641A (es)
PE (1) PE20121064A1 (es)
SG (1) SG176717A1 (es)
TW (1) TW201106961A (es)
UA (1) UA104762C2 (es)
WO (1) WO2010144265A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6193017B2 (ja) * 2013-06-28 2017-09-06 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ
JP6562902B2 (ja) 2014-03-28 2019-08-21 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017423A1 (en) * 1993-12-23 1995-06-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
JP2003501394A (ja) * 1999-06-04 2003-01-14 ノボ ノルディスク アクティーゼルスカブ 延長された重度の疾患の異化状態の処理のための組成物
US8263551B2 (en) * 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
CN101951937A (zh) * 2007-12-21 2011-01-19 赫尔辛医疗股份公司 使用伊帕瑞林刺激胃肠系统动力的方法
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну

Also Published As

Publication number Publication date
KR20120030530A (ko) 2012-03-28
ECSP11011516A (es) 2012-03-30
CL2011003131A1 (es) 2012-08-17
EP2440180A2 (en) 2012-04-18
WO2010144265A2 (en) 2010-12-16
UA104762C2 (ru) 2014-03-11
AU2010259102A1 (en) 2012-01-12
PE20121064A1 (es) 2012-09-03
GT201100318A (es) 2014-10-13
NZ596641A (en) 2013-12-20
EA201270011A1 (ru) 2012-05-30
CU20110232A7 (es) 2012-06-21
CR20110618A (es) 2012-03-02
MX2011013113A (es) 2012-02-21
DOP2011000383A (es) 2012-05-31
TW201106961A (en) 2011-03-01
BRPI1012931A2 (pt) 2018-01-30
CA2765233A1 (en) 2010-12-16
WO2010144265A3 (en) 2011-11-24
AU2010259102B2 (en) 2013-09-12
US20100317581A1 (en) 2010-12-16
JP2012529510A (ja) 2012-11-22
NI201100212A (es) 2012-04-11
EP2440180B1 (en) 2014-08-27
SG176717A1 (en) 2012-01-30
CN102481251A (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
CO6491065A2 (es) Formulación farmacéutica
PE20130511A1 (es) Formulaciones de insulina de accion prolongada
MX379353B (es) Compuesto de piperidina tipo quinoxalina sustituida y uso de los mismos.
AR081983A1 (es) Articulo de dosis unitaria soluble que comprende un polimero cationico
CO6640311A2 (es) Compuestos, composiciones de tioacetato y métodos de uso
BR112012023382A2 (pt) compostos, composições e métodos de uso de imidazopiridina.
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
MX2013004104A (es) Uso de una composicion que comprende un peptido antimicrobiano como un conservador de alimentos.
UY32731A (es) Nuevos derivados de piperidin-ilidenaminooxi-piperidin, composiciones farmacéuticas y métodos relacionados con ellos
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
SV2011003907A (es) Composiciones antimicrobianas
EP2643009A4 (en) COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
CL2011001132A1 (es) Metodo para reducir al minimo la inflamacion en el sitio de inyeccion durante la administracion subcutanea de una macromolecula que comprende agregar a una formulacion que contiene la macromolecula de 2% a 30% de ciclodextrina; formulacion que comprende un anticuerpo; y metodo para reducir al minimola precipitacion del anticuerpo.
EA201170512A1 (ru) Композиция для перорального введения
WO2014020405A8 (en) Cyclic urea- or lactam-substituted quinoxaline-type piperidine compounds and the uses thereof
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
BR112013009415A2 (pt) composto de éter arilóxidihalo-propenil e uso destes
CO6310996A2 (es) Composicion fungicida que contiene un compuesto de imidazol en combinación con polioxinas
CO6470880A2 (es) Soluciones para infusión e inyección de diacetato de ipamorelina.
BR112012013319A2 (pt) derivados espiro azacíclicos
NI201200196A (es) Agentes terapéuticos 976
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
TR200806302A2 (tr) Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
TR200806299A2 (tr) Çözünürlük artırıcı farmasötik formülasyon

Legal Events

Date Code Title Description
FC Application refused